Evaluating anti‐viral drug selection and treatment duration in HBeAg‐negative chronic hepatitis B: a cost‐effectiveness analysis

Background  Several anti‐viral treatments are now available for HBeAg‐negative chronic hepatitis B (CHB), but the clinical and economic outcomes of potential treatment strategies and durations are unclear.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  A. Levy,et al.  The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Ling-xia Zhang,et al.  [AASLD practice guidelines: chronic hepatitis B]. , 2007, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[4]  S. Hadziyannis,et al.  Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B , 2007, Hepatology.

[5]  R. Gish,et al.  Chronic hepatitis B: current epidemiology in the Americas and implications for management , 2006, Journal of viral hepatitis.

[6]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[7]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[8]  J. Shepherd,et al.  Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. , 2006, Health technology assessment.

[9]  Elisabeth Fenwick,et al.  Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation , 2006, BMC Health Services Research.

[10]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[11]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[12]  M. Buti,et al.  Chronic hepatitis B: a critical appraisal of current approaches to therapy. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[14]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[15]  A. Gurakar,et al.  Liver transplantation for hepatitis B in the United States. , 2005, Transplantation proceedings.

[16]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[17]  A. Lok.  The maze of treatments for hepatitis B. , 2005, The New England journal of medicine.

[18]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[19]  B. Spiegel,et al.  Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis , 2005, Annals of Internal Medicine.

[20]  P. Katsinelos,et al.  Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine‐resistant hepatitis B e antigen‐negative chronic hepatitis B , 2005, Alimentary pharmacology & therapeutics.

[21]  Thomas K. Hazlet,et al.  Global Epidemiology of Hepatitis B Virus , 2004, Journal of clinical gastroenterology.

[22]  U. Iloeje,et al.  Cost of Chronic Hepatitis B Infection in the United States , 2004, Journal of clinical gastroenterology.

[23]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[24]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[25]  W. Kim,et al.  Outcome of liver transplantation for hepatitis B in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[27]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[28]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[29]  E. Keeffe,et al.  Prevalence of HBV precore/core promoter variants in the United States , 2003, Hepatology.

[30]  M. Weinstein,et al.  Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. , 2003, JAMA.

[31]  F. Rousseau,et al.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.

[32]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[33]  E. Christensen,et al.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients , 2002, American Journal of Gastroenterology.

[34]  K. Chan,et al.  Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. , 2002, Journal of the Formosan Medical Association = Taiwan yi zhi.

[35]  H. Chiou,et al.  Long‐term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B , 2002, Hepatology.

[36]  P. Desmond,et al.  Introduction of lamivudine for the treatment of chronic hepatitis B: Expected clinical and economic outcomes based on 4‐year clinical trial data , 2002, Journal of gastroenterology and hepatology.

[37]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[38]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[39]  B. McMahon,et al.  Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus , 2001, Annals of Internal Medicine.

[40]  M. Sherman,et al.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis , 2001, Gut.

[41]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[42]  J. Hoofnagle,et al.  Chronic viral hepatitis--benefits of current therapies. , 1996, The New England journal of medicine.

[43]  A. Lok.  Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-Positive chronic hepatitis: Wong JB, Koff RS, Tine F, Pauker SG. B. Ann Intern Med 1995; 122: 664–675 , 1995 .

[44]  S. Pauker,et al.  Cost-effectiveness of Interferon-2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1995, Annals of Internal Medicine.

[45]  R. D. de Man,et al.  Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. , 1992, Gastroenterology.

[46]  F. Callea,et al.  Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. , 1986, Gastroenterology.

[47]  C. Chu,et al.  Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. , 1986, Gastroenterology.

[48]  T. Shikata,et al.  Two distinct types of hepatitis in experimental hepatitis B virus infection. , 1980, The American journal of pathology.

[49]  M. Yuen,et al.  Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential? , 2007, The American Journal of Gastroenterology.

[50]  P. Shiono,et al.  Characteristics of persons with chronic hepatitis B--San Francisco, California, 2006. , 2007, MMWR. Morbidity and mortality weekly report.

[51]  J. Shepherd,et al.  Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. , 2006, Health technology assessment.

[52]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .

[53]  M. Brunetto,et al.  'e' antigen defective hepatitis B virus and course of chronic infection. , 1991, Journal of hepatology.